Curriculum vitae
Saskia Biskup

Personal data

Name:	**Saskia Biskup, MD PhD**
Place of birth:	Frankfurt, Germany
Date of birth:	December 26th 1971
Citizenship:	German
Languages spoken:	German, English, French
Address:	CeGaT GmbH, Paul-Ehrlich-Str. 23, 72076 Tübingen, Germany
Phone:	+49 7071-565 44 00 / Fax: +49 7071-565 44 22
Email address:	saskia.biskup@cegat.de

Education

2009	University of Tübingen, Tübingen, Germany	Physician specialized in Human Genetics
2005-2008	Johns Hopkins Medical Institutions, Baltimore, USA	Neurogenetics with a focus on neurodegenerative diseases
2003-2005	University of Munich, Munich, Germany	Neurogenetics with a focus on Parkinson Syndrome
2003	University of Würzburg, Würzburg, Germany	PhD in Genetics
1999	University of Würzburg, Würzburg, Germany	MD

Positions and employment

2022-present	Co-Founder of the MVZ Zentrum für ambulante Onkologie Tübingen, Tübingen, Germany
2010-present	Founder and Owner of the Zentrum für Humangenetik Tübingen, Tübingen, Germany
2009-present	CEO & Co-Founder and Laboratory Director CeGaT GmbH, Tübingen, Germany
2005-2008	Research fellow (Human Genetics and Neurogenetics) at the Johns Hopkins University, Baltimore, USA
2002-2005	Research fellow (Human Genetics and Neurogenetics) at the Technical University Munich, Germany

Scientific achievement

h-index 48; > 200 peer reviewed publications, > 9.000 citations

Subspecializations in Human Genetics

- Tumor Diagnostics
- Neurodegenerative Diseases
- Neuromuscular Diseases
- Brain Development Diseases
- Epileptic Disorders & Migraines
- Ion Channel Diseases
- Mitochondriopathies

Professional Memberships

- German Society of Human Genetics
- European Society of Human Genetics
- American Society of Human Genetics
- German Society of Neurogenetics

Honors

2014	EU Prize for Women Innovators
2013	Ernst & Young "Entrepreneur of the Year"
2011	German Founder´s Award Category Start up
2006	Peter Gruber Foundation International Young Scientist Award
2005	International Congress of Parkinson's Disease Young Scientist Award

Publications

2023 Schmidt M, Mattern S, Singer S, Schulze M, **Biskup S**, Krumm P, Lauer UM, Zender L, Hinterleitner C, Hinterleitner M. *NOTCH3 missense mutations as predictor of long-term response to gemcitabine in a patient with epithelioid hemangioendothelioma.* J Cancer Res Clin Oncol. 2023 Feb 7. doi: 10.1007/s00432-023-04598-1. Epub ahead of print. PMID: 36749424.

2022 Zelba H, McQueeney A, Rabsteyn A, Bartsch O, Kyzirakos C, Kayser S, Harter J, Latzer P, Hadaschik D, Battke F, Hartkopf AD, **Biskup S**. *Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination-A Retrospective Observation.* Vaccines (Basel). 2022 Nov 8;10(11):1882. doi: 10.3390/vaccines10111882. PMID: 36366390; PMCID: PMC9698403.

2022 Forschner A, Niessner H, Sinnberg T, Eigentler T, Amaral T, Seith F, Garbe C, **Biskup S**, Battke F. *Zirkulierende Tumor-DNA (ctDNA) bei der Entdeckung von Rezidiven bei Melanompatienten mit adjuvanter Anti-PD-1-Therapie.* J Dtsch Dermatol Ges. 2022 Jun;20(6):867-871. doi: 10.1111/ddg.14766_g. PMID: 35711040.

2022 Cordts I, Önder D, Traschütz A, Kobeleva X, Karin I, Minnerop M, Koertvelyessy P, **Biskup S**, Forchhammer S, Binder J, Tzschach A, Meiss F, Schmidt A, Kreiß M, Cremer K, Mensah MA, Park J, Rautenberg M, Deininger N, Sturm M, Lingor P, Klopstock T, Weiler M, Marxreiter F, Synofzik M, Posch C, Sirokay J, Klockgether T, Haack TB, Deschauer M. *Adult-Onset Neurodegeneration in Nucleotide Excision Repair Disorders (NERDND): Time to Move Beyond the Skin.* Mov Disord. 2022 Aug;37(8):1707-1718. doi: 10.1002/mds.29071. Epub 2022 Jun 14. PMID: 35699229.

2022 Forschner A, Niessner H, Sinnberg T, Eigentler T, Amaral T, Seith F, Garbe C, **Biskup S**, Battke F. *Circulating tumor DNA (ctDNA) in the detection of relapse in melanoma patients with adjuvant anti-PD-1 therapy.* J Dtsch Dermatol Ges. 2022 Jun;20(6):867-871. doi: 10.1111/ddg.14766. Epub 2022 May 12. PMID: 35555861.

2022 Michaeli O, Ladany H, Erez A, Ben Shachar S, Izraeli S, Lidzbarsky G, Basel-Salmon L, **Biskup S**, Maruvka YE, Toledano H, Goldberg Y. *Di-genic inheritance of germline POLE and PMS2 pathogenic variants causes a unique condition associated with pediatric cancer predisposition.* Clin Genet. 2022 Apr;101(4):442-447. doi: 10.1111/cge.14106. Epub 2022 Jan 7. PMID: 34967012.

2021 Bitzer M, Spahn S, Babaei S, Horger M, Singer S, Schulze-Osthoff K, Missios P, Gatidis S, Nann D, Mattern S, Scheble V, Nikolaou K, Armeanu-Ebinger S, Schulze M, Schroeder C, **Biskup S**, Beha J, Claassen M, Ruhm K, Poso A, Malek NP. *Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma.* NPJ Precis Oncol. 2021 Sep 3;5(1):80. doi: 10.1038/s41698-021-00220-0. PMID: 34480077; PMCID: PMC8417271.

2021 Voith von Voithenberg L, Kashyap A, Opitz L, Aquino C, Sykes T, Nieser M, Petrini LFT, Enrriquez Casimiro N, van Kooten XF, **Biskup S**, Schlapbach R, Schraml P, Kaigala GV. *Mapping Spatial Genetic Landscapes in Tissue Sections through Microscale Integration of Sampling Methodology into Genomic Workflows.* Small. 2021 Jun;17(23):e2007901. doi: 10.1002/smll.202007901. Epub 2021 Apr 14. PMID: 33852760.

2021 Castro MP, Afshar M, Williams C, Turcat T, Parker D, Gordon E, Zambelli J, McDonald A, Suh C, Baylon S, **Biskup S**. *Utility of Serial Transcriptomic Analyses to Characterize the Resistome and to Refine Treatment Selection for Metastatic Colon Cancer: Case Report.* Clin Colorectal Cancer. 2021 Mar;20(1):96-99. doi: 10.1016/j.clcc.2020.10.003. Epub 2020 Oct 24. PMID: 33353848.

2021 Zelba H, Worbs D, Harter J, Pieper N, Kyzirakos-Feger C, Kayser S, Seibold M, Bartsch O, Ködding J, **Biskup S**. *A Highly Specific Assay for the Detection of SARS-CoV-2-Reactive CD4+ and CD8+ T Cells in COVID-19 Patients.* J Immunol. 2021 Feb 1;206(3):580-587. doi: 10.4049/jimmunol.2000811. Epub 2020 Dec 9. PMID: 33298615.

2021 Blumendeller C, Boehme J, Frick M, Schulze M, Rinckleb A, Kyzirakos C, Kayser S, Kopp M, Kelkenberg S, Pieper N, Bartsch O, Hadaschick D, Battke F, Stenzl A, **Biskup S**. *Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report*. J Immunother Cancer. 2021 Jan;9(1):e001406. doi: 10.1136/jitc-2020-001406. PMID: 33431630; PMCID: PMC7802705.

2020 Spahn S, Roessler D, Pompilia R, Gabernet G, Gladstone BP, Horger M, **Biskup S**, Feldhahn M, Nahnsen S, Hilke FJ, Scheiner B, Dufour JF, De Toni EN, Pinter M, Malek NP, Bitzer M. *Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers* (Basel). 2020 Dec 18;12(12):3830. doi: 10.3390/cancers12123830. PMID: 33353145; PMCID: PMC7766321.

2020 Schittenhelm J, Ziegler L, Sperveslage J, Mittelbronn M, Capper D, Burghardt I, Poso A, **Biskup S**, Skardelly M, Tabatabai G. *FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma.* Neurooncol Pract. 2020 Nov 20;8(2):209-221. doi: 10.1093/nop/npaa075. PMID: 33898054; PMCID: PMC8049444.

2020 Walter C, Hartkopf A, Koch A, Klaumünzer M, Schulze M, Grischke EM, Taran FA, Brucker S, Battke F, **Biskup S**. *Sequencing for an interdisciplinary molecular tumor board in patients with advanced breast cancer: experiences from a case series.* Oncotarget. 2020 Sep 1;11(35):3279-3285. doi: 10.18632/oncotarget.27704. PMID: 32934773; PMCID: PMC7476733.

2020 Forschner A, Weißgraeber S, Hadaschik D, Schulze M, Kopp M, Kelkenberg S, Sinnberg T, Garbe C, **Biskup S**, Battke F. *Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker Study.* Onco Targets Ther. 2020 Jun 4;13:5017-5032. doi: 10.2147/OTT.S248237. PMID: 32581559; PMCID: PMC7280255.

2020 Cöktü S, Spix C, Kaiser M, Beygo J, Kleinle S, Bachmann N, Kohlschmidt N, Prawitt D, Beckmann A, Klaes R, Nevinny-Stickel-Hinzpeter C, Döhnert S, Kraus C, Kadgien G, Vater I, **Biskup S**, Kutsche M, Kohlhase J, Eggermann T, Zenker M, Kratz CP. Cancer incidence and spectrum among children with genetically confirmed Beckwith-Wiedemann spectrum in Germany: a retrospective cohort study. Br J Cancer. 2020 Aug;123(4):619-623. doi: 10.1038/s41416-020-0911-x. Epub 2020 May 26. PMID: 32451468; PMCID: PMC7434760.

2020 Amaral T, Schulze M, Sinnberg T, Nieser M, Martus P, Battke F, Garbe C, **Biskup S**, Forschner A. Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy? Cancers (Basel). 2020 Apr 28;12(5):1101. doi: 10.3390/cancers12051101. PMID: 32354124; PMCID: PMC7281129.

2020 Bitzer M, Ostermann L, Horger M, **Biskup S**, Schulze M, Ruhm K, Hilke F, Öner Ö, Nikolaou K, Schroeder C, Riess O, Fend F, Zips D, Hinterleitner M, Zender L, Tabatabai G, Beha J, Malek NP. *Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options.* JCO Precis Oncol. 2020 Mar 30;4:PO.19.00359. doi: 10.1200/PO.19.00359. PMID: 32923905; PMCID: PMC7446530.

2020 Brenner E, Schörg BF, Ahmetlić F, Wieder T, Hilke FJ, Simon N, Schroeder C, Demidov G, Riedel T, Fehrenbacher B, Schaller M, Forschner A, Eigentler T, Niessner H, Sinnberg T, Böhm KS, Hömberg N, Braumüller H, Dauch D, Zwirner S, Zender L, Sonanini D, Geishauser A, Bauer J, Eichner M, Jarick KJ, Beilhack A, **Biskup S**, Döcker D, Schadendorf D, Quintanilla-Martinez L, Pichler BJ, Kneilling M, Mocikat R, Röcken M. *Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours.* Nat Commun. 2020 Mar 12;11(1):1335. doi: 10.1038/s41467-020-14987-6. PMID: 32165639; PMCID: PMC7067802.

2019 Forschner A, Battke F, Hadaschik D, Schulze M, Weißgraeber S, Han CT, Kopp M, Frick M, Klumpp B, Tietze N, Amaral T, Martus P, Sinnberg T, Eigentler T, Keim U, Garbe C, Döcker D, **Biskup S**. *Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study*. J Immunother Cancer. 2019 Jul 12;7(1):180. doi: 10.1186/s40425-019-0659-0. PMID: 31300034; PMCID: PMC6625062.

2019 Hickmann AK, Frick M, Hadaschik D, Battke F, Bittl M, Ganslandt O, **Biskup S**, Döcker D. *Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.* BMC Cancer. 2019 Mar 1;19(1):192. doi: 10.1186/s12885-019-5394-x. PMID: 30823914; PMCID: PMC6397454.

2018 Berger S, Bochum S, Finkeisen D, Schilliro A, Autschbach F, Bischof M, Hagmueller E, Pereira PL, Weickert U, Sipos B, **Biskup S**, Martens UM. *Sustainable Response of a Patient With Metastasized Pancreatic Cancer and a Hypermutational Phenotype to Immunotherapy. New Therapeutic Concept for a Rare Subtype?* JCO Precis Oncol. 2018 Nov;2:1-6. doi: 10.1200/PO.18.00005. PMID: 35135127.